基本信息
浏览量:2
职业迁徙
个人简介
Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier. His thesis work led to the development and application of light energy transfer methodology for the study of protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under the supervision of Dr. Randall T. Moon, where he identified and characterized novel components of the Wnt signalling pathway and a new class of E3 ubiquitin ligases.
In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and in the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signalling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signalling mechanisms in development, adult tissue homeostasis and in human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics and AntlerA Therapeutics, which are pursuing the clinical development of these molecules.
In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and in the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signalling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signalling mechanisms in development, adult tissue homeostasis and in human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics and AntlerA Therapeutics, which are pursuing the clinical development of these molecules.
研究兴趣
论文共 221 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
DEVELOPMENTno. 5 (2024)
Science advancesno. 19 (2024): eadj1468-eadj1468
Hideyuki Komori, Geeta Rastogi, John Paul Bugay,Hua Luo,Sichun Lin,Stephane Angers,Craig A Smibert,Howard D Lipshitz,Cheng-Yu Lee
bioRxiv : the preprint server for biology (2024)
Andy Yang,Rony Chidiac, Emma Russo,Hendrik Steenland, Quinn Pauli,Robert Bonin,Levi L. Blazer,Jarrett J. Adams,Sachdev S. Sidhu, Aleksandrina Goeva,Ali Salahpour,Stephane Angers
DEVELOPMENTno. 5 (2024)
Yassine El Bakkouri,Rony Chidiac,Chantal Delisle, Jeanne Corriveau,Gael Cagnone, Vanda Gaonac'h-Lovejoy, Ashley Chin, Éric Lécuyer,Stephane Angers,Jean-Sébastien Joyal,Ivan Topisirovic,Laura Hulea,
Nature communicationsno. 1 (2024): 4405-4405
Nuclear medicine and biology (2023): 108367-108367
Benoît Vanderperre, Amitha Muraleedharan,Frédérique Larroquette,Rony Chidiac, Charlotte Tardif,Nishani Rajakulendran,Graham Macleod,Roxanne Larivière,Esther Del Cid Pellitero,Rhalena Thomas,Thomas Durcan,Stephane Angers,
IBRO Neuroscience Reports (2023): S459-S459
Nucleic Acids Researchno. 12 (2023): 6461-6478
Mahmoud Labib,Zongjie Wang, Yunhye Kim,Sichun Lin,Abdalla Abdrabou,Hanie Yousefi, Pei-Ying Lo,Stéphane Angers,Edward H Sargent,Shana O Kelley
Nature biomedical engineeringno. 3 (2023): 1-15
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn